scholarly journals Positive Results of Serum Galactomannan Assays and Pulmonary Computed Tomography Predict the Higher Response Rate of Empirical Antifungal Therapy in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

2011 ◽  
Vol 17 (5) ◽  
pp. 759-764 ◽  
Author(s):  
Yu Ji ◽  
Lan-ping Xu ◽  
Dai-hong Liu ◽  
Yu-hong Chen ◽  
Wei Han ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Response Rate ◽  
Hematopoietic Stem ◽  
Empirical Antifungal Therapy ◽  
Positive Results

scholarly journals Early Lung Computed Tomography Scan after Allogeneic Hematopoietic Stem Cell Transplantation

2016 ◽  
Vol 22 (8) ◽  
pp. 1511-1516
Author(s):  
Marie Alice Cornetto ◽  
Sylvie Chevret ◽  
Sarah Abbes ◽  
Constance de Margerie-Mellon ◽  
Claire Hussenet ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Computed Tomography Scan ◽  
Hematopoietic Stem ◽  
Tomography Scan

Gemcitabine-Based Salvage Chemotherapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for the Patients with Relapse of Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2822-2822
Author(s):  
Anna Czyz ◽  
Adam Nowicki ◽  
Lidia Gil ◽  
Dominik Dytfeld ◽  
Anna Lojko-Dankowska ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Response Rate ◽  
Salvage Chemotherapy ◽  
Hematopoietic Stem ◽  
Reduced Intensity

Abstract Abstract 2822 An optimal therapy for patients with Hodgkin lymphoma (HL) who experience relapse after autologous hematopoietic stem cell transplantation (autoHSCT) has not been established. Gemcitabine has been shown to be effective in patients with relapsed or refractory lymphoma. We evaluated the efficacy and safety of gemcitabine-based chemotherapy in 22 patients (median age 33 years, range 23–56 years) with relapse of HL at a median of 7 months (range 3–82) after autoHSCT preceded by a median of 3 (range 2–6) previous chemotherapy lines. Two patients relapsed after autoHSCT followed by allogeneic hematopoietic stem cell transplantation (alloHSCT). The patients received a median of 3 (range 1–4) gemcitabine-based chemotherapy courses with filgastrim support. Fourteen of patients received regimen which consisted of gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on days 1, 8 and 15 given every 28 days and eight of patients received gemcitabine 1000 mg/m2 on days 1, 8 and 15, cisplatin 100 mg/m2 on day 1 and methylprednisolone 1000 mg/m2 on days 1–4 of a treatment cycle repeated every 28 days. Twenty of the 22 patients were treated with the intent to proceed to reduced intensity alloHSCT. Two patients with relapse of HL after autoHSCT followed by alloHSCT were treated with the intent to proceed to donor lymphocyte infusion (DLI). Results: A toxicity of a total 60 gemcitabine-based cycles was analyzed. The dose of gemcitabine was omitted, delayed or reduced due to neutropenia or thrombocytopenia in 22/60 (33%) cycles. Neutropenia < 0,5 G/L occurred in 20/60 (33%) and thrombocytopenia < 20 G/L in 19/60 (32%) cycles. Two patients were thrombocytopenic before gemcitabine treatment. Seven of the 60 (12%) cycles were complicated by infection grade 3–4 according to NCI CTC (neutropenic febrile- 2 episodes, pneumonia- 5 episodes). Transient liver enzymes elevation grade 2 occurred in 2/60 (3%) cycles in 1 patient. The overall response rate was 64% (14/22 pts), with 6 CR confirmed by PET/CT and 8 PR. At the time of analysis 9 patients have proceeded to reduced intensity alloHSCT and 2 patients after prior autoHSCT and alloHSCT to DLI. After a median follow-up of 8 months (range 3–38) 11/22 patients remain alive. OS for all 22 patients was 39% (95% CI 14–64) at 24 months estimated with the Kaplan-Meier method. OS according to the response to gemcitabine-based salvage chemotherapy was 47% for patients who achieved CR/PR after treatment and 23% for refractory patients (p ns). Median of PFS for patients with response to gemcitabine-based chemotherapy was 8 (95% CI 5–11) months. Conclusion: Our observational study confirms that gemcitabine-based chemotherapy is a feasible regimen with significant response rate and acceptable toxicity profile in heavily pre-treated patients with relapse of HL after autoHSCT. However, the response duration is short and gemcitabine-based chemotherapy appears to be a treatment option to provide a bridge to alloHSCT. Disclosures: No relevant conflicts of interest to declare.

Hematopoietic stem cell transplantation and rhinosinusitis: The utility of screening sinus computed tomography

2012 ◽  
Vol 122 (12) ◽  
pp. 2647-2651 ◽  
Author(s):  
Susan Fulmer ◽  
Sung-won Kim ◽  
Jess C. Mace ◽  
Matthew E. Leach ◽  
Sergey Tarima ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem

scholarly journals Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications

2021 ◽  
Vol 15 (1) ◽  
pp. 66-72
Author(s):  
O. B. Ovsyannikova ◽  
L. P. Ananyeva ◽  
O. A. Koneva ◽  
L. A. Garzanova ◽  
O. V. Desinova ◽  
...  
Keyword(s):  
Stem Cell ◽  
Systemic Sclerosis ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Causes Of Death ◽  
Controlled Clinical Trials ◽  
Hematopoietic Stem ◽  
Positive Results

Autologous hematopoietic stem cell transplantation (auto-HSCT) is presently the only disease-modifying strategy for the treatment of systemic sclerosis (SSs) that has Level A evidence, the effectiveness of which has been proven in three controlled clinical trials: ASSIST, ASTIS, and SCOT. Despite the positive results obtained with the use of this treatment option, the issues related to its tolerability and safety remain unresolved. The complications caused by obvious immunosuppression and higher frequency of infections are the main causes of death after autoHSCT for autoimmune diseases and occur mainly in the first month after treatment. Overall, the studies performed confirm the overall assessment of auto-HSCT as an effective and relatively safe treatment for severe SSs.

scholarly journals Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update

2017 ◽  
Vol 35 (18) ◽  
pp. 2082-2094 ◽  
Author(s):  
Thomas Lehrnbecher ◽  
Paula Robinson ◽  
Brian Fisher ◽  
Sarah Alexander ◽  
Roland A. Ammann ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Risk Stratification ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Antifungal Therapy ◽  
Hematopoietic Stem ◽  
Empirical Antifungal Therapy

Purpose To update a clinical practice guideline (CPG) for the empirical management of fever and neutropenia (FN) in children with cancer and hematopoietic stem-cell transplantation recipients. Methods The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and multinational group of experts in pediatric oncology and infectious diseases that includes a patient advocate. For questions of risk stratification and evaluation, we updated systematic reviews of observational studies. For questions of therapy, we conducted a systematic review of randomized trials of any intervention applied for the empirical management of pediatric FN. The Grading of Recommendation Assessment, Development and Evaluation approach was used to make strong or weak recommendations and to classify levels of evidence as high, moderate, low, or very low. Results Recommendations related to initial presentation, ongoing management, and empirical antifungal therapy of pediatric FN were reviewed; the most substantial changes were related to empirical antifungal therapy. Key differences from our 2012 FN CPG included the listing of a fourth-generation cephalosporin for empirical therapy in high-risk FN, refinement of risk stratification to define patients with high-risk invasive fungal disease (IFD), changes in recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and a weak recommendation to withhold empirical antifungal therapy in IFD low-risk patients with prolonged FN. Conclusion Changes to the updated FN CPG recommendations will likely influence the care of pediatric patients with cancer and those undergoing hematopoietic stem-cell transplantation. Future work should focus on closing research gaps and on identifying ways to facilitate implementation and adaptation.

Sign in / Sign up

Export Citation Format

Share Document